Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PTC Therapeutics -- PTCT -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (5)	1/26/2014 11:58:34 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 38

This brilliant exchange on twitter today re. CD123 (MGNX, XNCR).... Andy Biotech ?@AndyBiotech 18h @DrMiguelPerales Penn CD123 CART showed nice efficacy in mice but also clear BM tox, heard they won't pursue further ash.confex.com … Reply Retweet Favorite More Expand Miguel Perales M.D. ?@DrMiguelPerales 18h @AndyBiotech BM Toxicity of CD123 CART could be built into Allo-HCT conditioning - need to make sure CART are gone when donor graft goes in Reply Retweet Favorite More Expand Andy Biotech ?@AndyBiotech 18h @DrMiguelPerales Thx! Is it better to target CD123 w mAbs, bi-specific CD3xCD123 Abs or ADCs given the safety concerns and narrow Tx window? Reply Retweet Favorite More Expand Miguel Perales M.D. ?@DrMiguelPerales 18h @AndyBiotech Pros & cons to bi-spec Abs vs CART in general. At this stage, we should explore both. For CD123 bi-spec may have better profile Reply Retweet Favorite More Expand Andy Biotech ?@AndyBiotech 18h @DrMiguelPerales Agreed and it's clearly on industry's radar, both $MGNX and $XNCR have CD123 bi-spec in development ash.confex.com … Hide conversation Reply Retweet Favorite More 2Retweets 1Favorite jjz Miguel Perales M.D. 9:43 AM - 26 Jan 2014 · Details